https://scholars.lib.ntu.edu.tw/handle/123456789/189607
標題: | Prospective Study of Warfarin Dosage Requirements Based on Cyp2c9 and Vkorc1 Genotypes | 作者: | WEN, MING-SHIEN LEE, MING-TA MICHAEL CHEN, JIN-JER CHUANG, HUI-PING LU, LIANG-SUEI CHEN, CHIEN-HSIUN LEE, TSONG-HAI KUO, CHI-TAI KUAN, PEI-LIANG CHEN, YING-FU WU, JER-YUARN CHEN, YUAN-TSONG |
公開日期: | 2008 | 起(迄)頁: | 83-89 | 來源出版物: | Clinical Pharmacology & Therapeutics | 摘要: | Polymorphisms in CYP 2C9 and VKOR C1 have been shown to be associated with warfarin dose requirements and could be used to predict warfarin dose . We conducted a prospective study in which warfarin dose was prescribed based on CYP 2C9 and VKOR C1 polymorphisms in 108 Han-Chinese patients without prior warfarin treatments. Using the genotype-based dosing, 83% of patients reached stable, therapeutic international normalized ratio (INR ) within 2 weeks of treatment initiation and none of the patients developed clinical bleeding or thromboembolic event. Ten percent (11) of patients with INR >4 and no clinical bleeding were detected during this study. At 12 weeks, 69% of the patients’maintenance doses matched the prediction. Dosing algorithms incorporating genetic factors, age, and body surface area were developed, which could explain up to 62% of the total variation (R2 of 0.62). This study demonstrated that pharmacogenetics- based dosing could improve time to stable, therapeutic INR , reduce adverse events, and achieve high sensitivity. |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/174612 | DOI: | 10.1038/sj.clpt.6100453 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。